Relates to Heterocyclic compounds of formula (i) wherein R1 is CN, cycloalkyl (C3 and C6), a bicyclic Group (c8-c10), among others phenyl, R2 is H, CN, halogen, alkyl (c1-c4), among others R3 is absent or is H or alkyl (C1 - C4) R4 is alquileno (c1-c4) - R5, cicloalquileno (C3 C6) - R5, co - CH2 - R5, in Where R5 is Oh, opo3h2 PO3H2, among others Z - W - (alquileno NS) - T -, where w IS - O -, co -, - S -,- NH -, - C? - CH2 - C -, o -, among others t is a Link, - O -, - S -, - NH -, co -, among others n is 0 to 10 a is a Ring that may contain nitrogen Q is a cyclic Amine of 5 to 7 members X it is c or N and is o, NH, or S.Preferred compounds are: acid 3 - (2 - [4 - (2 - fluoro - Benzyloxy) - phenyl] - 6.7 - dihydro - 4 - furo [c] pyridine - 2 - 5 - il} - {3 - propionic acid 2 - [4 - (trifluoromethyl) - 2 - (Benzyloxy) fluoro phenyl] - 6.7 - dihydro - H - oxazolo [4,5-c] pyridine - il - 5} - 2 - Methyl propionic acid 4 - (2 - [4 - (2,3 - difluoro - Benzyloxy - 2 - methyl) phenyl] - 6 7 - dihydro - 4 - oxazolo [4,5-c] - pyridin - il - 5} - pentanoic acid among others.It also relates to a Pharmaceutical composition. These compounds are receptor modulators of sphingosine 1-phosphate (S1P) being useful in the treatment of Alzheimers disease, dementia, AutismSE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE R1 ES CN, CICLOALQUILO(C3-C6), UN GRUPO BICICLICO(C8-C10), FENILO, ENTRE OTROS R2 ES H, CN, HALOGENO, ALQUILO(C1-C4), ENTRE OTROS R3 ESTA AUSENTE O ES H O ALQUILO(C1-C4) R4 ES ALQUILENO(C1-C4)-R5, CICLOALQUILENO(C3-C6)-R5, CO-CH2-R5, EN DONDE R5 ES OH, PO3H2, OPO3H2, ENTRE OTROS Z ES -W-(ALQUILENO Cn)-T-, EN DONDE W ES -O-, -CO-, -S-, -NH-, -C?C-, -CH2-O-, ENTRE OTROS T ES UN ENLACE, -O-, -S-, -NH-, -CO-, ENTRE OTROS n ES DE 0 A 10 A ES UN ANILLO QUE PUEDE CONTENER NITROGENO Q ES UNA AMINA CICLICA DE 5 A 7 MIEMBROS X ES C O N Y ES O, NH O S. SON COMPUESTOS PREFERIDOS: ACIDO 3-{2-[4-(2-FLUORO-BENCILOXI)-FENIL]-6,7-DIHIDRO-4H-FURO[3,2-c]PIRIDINA-5-IL}-PROPIONIC
